Client's-News

Innovation

7. August 2018

Vienna-based biotech company Marinomed obtains EU-wide certification for new cold medication

 

  • New combination reduces blocked nose without a pharmaceutical ingredient while simultaneously combating viral airway infections
  • Patent application submitted for innovative formulation

 

Vienna, 7 August 2018.  Vienna-based company Marinomed Biotech AG (Marinomed) today announced it had secured EU-wide certification for a new product: a nasal spray that allows the decongestion of the nasal cavity without employing a pharmaceutical ingredient and tackles viral infections of the airways at the same time. The groundbreaking combination is based on a formulation for which Marinomed has submitted a patent application. This would allow the company to use its patented agent Carragelose®, which targets cold viruses, in such a combination.

 

“With this certification our new product is marketable throughout the EU,” explained Dr. Eva Prieschl-Grassauer, Marinomed’s founder and a member of the company’s management board. “This year we will launch the product in Austria – under the brand name Coldamaris akut – and in Switzerland.” As a result, Marinomed is set to further expand its product range, which currently comprises of five different products including nasal, throat sprays and lozenges, available in over 30 countries.

 

All Marinomed products launched to date are effective against cold viruses. Their efficacy is based on Carragelose®, a polymer derived from red seaweed with a special, clinically proven, efficacy against viral respiratory infections. Carragelose® traps cold viruses, stopping them from infecting mucousal cells. The polymer also soothes and moistens the mucosa.

 

A new formulation has been developed in Marinomed’s laboratories in order to optimize the efficacy of Carragelose® with the addition of a decongestant effect based on increased osmolality. Instead of sodium chloride (NaCl), which also has an osmotic effect, a new formulation is used to retain the activity of Carragelose® against viruses infecting the respiratory tract. Certification of the newly developed, innovative product for sale in the EU reaffirms Marinomed’s strategy of continuously product development.

 

 

About Marinomed Biotech AG

Marinomed is a Vienna based biopharmaceutical company focusing on the development of innovative products in the field of respiratory and ophthalmological diseases based on its IP protected technology platforms.

The platform Carragelose® comprises innovative patent protected products targeting viral infections of the respiratory tract. Carragelose® is used in nasal and throat sprays and lozenges, which are sold in more than 30 countries around the world in collaboration with international partners.

Marinosolv© is a patent protected technology platform increasing the bioavailability of hardly soluble compounds for the treatment of sensitive tissues such as nose and eyes.

Further information is available at www.marinomed.comand www.carragelose.com.

 

Contact – Marinomed:

Dr Eva Prieschl-Grassauer

Chief Scientific Officer

Veterinärplatz 1

1210 Vienna, Austria

Tel. +43 (0)1 25077 4460

E-mail: eva.prieschl@marinomed.com

http://www.marinomed.com

 

Contact for media requests:

PR&D – Public Relations for Research & Education

Mariannengasse 8

1090 Vienna, Austria

Tel. +43 (0)1 5057044

E-mail: contact@prd.at

http://www.prd.at